Drug Development

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

Anika Therapeutics posts strong Q1 results with a 13% revenue jump, but analyst caution lingers over pipeline risks and long-term sustainability.

Genomics' big data and Greywolf's novel drugs unite to develop first-in-class treatments for autoimmune diseases, promising a new era of precision medicine.

By emphasizing deep anatomical knowledge, Medytox aims to elevate industry standards and solidify its leadership in Asia's booming medical aesthetics market.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

With the hire of world-renowned surgeon Dr. Nelson Oyesiku, Piedmont Healthcare signals its ambition to become a top destination for neurological care in the Southeast.

Following a breakthrough in chondrosarcoma, Inhibrx Biosciences is set to reveal pivotal data for its drug ozekibart in the vast colorectal cancer market.

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

A new alcohol-free, no-refrigeration blood pressure liquid aims to transform daily treatment for children, reflecting a key industry shift.

A Swiss-Indian partnership aims to halt diseases like Alzheimer's and ALS by repairing damaged cell membranes, a groundbreaking approach to a global crisis.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

A surprise $5 million pledge for glaucoma research highlights a gala honoring philanthropist Daria Barry, patient advocate Hillary Golden, and music icon Nile Rodgers.

Byondis presents two novel ADC platforms at AACR 2026, aiming to solve drug resistance and offer hope for patients unresponsive to immunotherapy.

Patients, doctors, and researchers unite for a grueling ride across Iceland, raising funds and hope for a future free from multiple myeloma.

A Chinese biotech has won a key approval for a novel antibody designed to fight deadly leukemias with enhanced safety, marking a new frontier in cancer care.

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

With backing from AI leaders, Helical’s virtual lab aims to turn powerful models into reproducible drug discovery systems, tackling a key industry bottleneck.

Eli Lilly acquires CrossBridge Bio for its innovative dual-payload ADC platform, signaling a major push into the next wave of targeted cancer treatments.

Renaissance Pharma's Daretabart gains FDA support for high-risk neuroblastoma, accelerating its journey to patients and offering new hope against this rare disease.